ALX-0171: Phase I started

Ablynx began an open-label, Belgian Phase I trial to evaluate a single dose of 0.3 mg/kg IV ALX-0171 and 200 mg inhaled ALX-0171 given as a single dose or once daily for 5 days in about 41 healthy mal...